Please use this identifier to cite or link to this item:
Title: Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury.
Authors: Schwaeble, WJ
Lynch, NJ
Clark, JE
Marber, M
Samani, NJ
Ali, YM
Dudler, T
Parent, B
Lhotta, K
Wallis, R
Farrar, CA
Sacks, S
Lee, H
Zhang, M
Iwaki, D
Takahashi, M
Fujita, T
Tedford, CE
Stover, CM
First Published: 3-May-2011
Citation: PROC NATL ACAD SCI U S A, 2011, 108 (18), pp. 7523-7528
Abstract: Complement research experienced a renaissance with the discovery of a third activation route, the lectin pathway. We developed a unique model of total lectin pathway deficiency, a mouse strain lacking mannan-binding lectin-associated serine protease-2 (MASP-2), and analyzed the role of MASP-2 in two models of postischemic reperfusion injury (IRI). In a model of transient myocardial IRI, MASP-2-deficient mice had significantly smaller infarct volumes than their wild-type littermates. Mice deficient in the downstream complement component C4 were not protected, suggesting the existence of a previously undescribed lectin pathway-dependent C4-bypass. Lectin pathway-mediated activation of C3 in the absence of C4 was demonstrated in vitro and shown to require MASP-2, C2, and MASP-1/3. MASP-2 deficiency also protects mice from gastrointestinal IRI, as do mAb-based inhibitors of MASP-2. The therapeutic effects of MASP-2 inhibition in this experimental model suggest the utility of anti-MASP-2 antibody therapy in reperfusion injury and other lectin pathway-mediated disorders.
DOI Link: 10.1073/pnas.1101748108
eISSN: 1091-6490
Type: Journal Article
Appears in Collections:Published Articles, Dept. of Cardiovascular Sciences

Files in This Item:
There are no files associated with this item.

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.